Instil Bio (TIL) Net Margin (2020)
Instil Bio (TIL) posted Net Margin of 13965.38% for Q3 2020, up 36.26% on a QoQ basis from 21909.52% in Q2 2020.
Powered by 
Analysis
Instil Bio (TIL) Net Margin (2020) Analysis & Trends
Instil Bio has reported Net Margin for 1 years, with the latest figure at 13965.38% in Q3 2020.
- On a quarterly basis, Net Margin changed N/A year-over-year to 13965.38% in Q3 2020; TTM through Jun 2021 was 159396.15%, a N/A change from a year earlier, with the FY2020 full-year figure at 27346.38%, changed N/A from the prior year.
- Net Margin was 13965.38% for Q3 2020 at Instil Bio, up from 21909.52% in the prior quarter.
- The five-year high for Net Margin was 9293.18% in Q1 2020, with the low at 21909.52% in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 23.62% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -134.51% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 32.99% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.23% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 31.16% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -539.31% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 12.74% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 3.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -20,152.98% |
| 10 | Instil Bio | 50.19 Mn | 50.19 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2020 | -13,965.38% |
| Jun 30, 2020 | -21,909.52% |
| Mar 31, 2020 | -9,293.18% |